Healio13h
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Health and Me on MSN2h
Yearly Jab For HIV Protection Is Now Almost Here
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
MIT Technology Review21h
The Download: HIV prevention shots, and fixing a broken sex doll
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
The Financial Express22h
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
Barchart on MSN22h
Gilead Sciences - Leader in HIV Medicines
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
MIT Technology Review1m
Now read the rest of The Algorithm
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection. What will really matter in the long run? That’s the question we tackle each year as ...
University of Utah Health19h
U Biochemist Receives National Honor for Outstanding Contributions in Basic Research
In a ceremony held last month, the 2024 Louisa Gross Horwitz Prize was awarded to Wesley Sundquist, PhD, Leo T. and Barbara K ...
Applied Clinical Trials Online20h
Phase III Trial Finds Baricitinib Boosts Hair Regrowth in Adolescents With Severe Alopecia Areata
The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...